Consensus Outlook Therapeutics, Inc.

Stocks

OTLK

US69012T3059

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 20:25:33 20/08/2026 +03			5-day change	1st Jan Change
0.6770 ^USD	-1.90%		-23.63%	-57.04%

08-17	EyePoint's drug for age-related eye disease fails late-stage trial, shares tank	RE
08-17	Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing	MT

Evolution of the Average Target: Outlook Therapeutics, Inc.

Evolution of the Target Price: Outlook Therapeutics, Inc.

Changes in Analyst Recommendations: Outlook Therapeutics, Inc.

4849653bd156817135b1550828b94.vKqrdYcikEpxEKmdl4VjYwKFW0D6YPKil7JgpVerdB0.1pmfQbZLvQcLVOXp87IELXjxNRWIEoTRwfsI3QLjEljx3fsAqg_1JUl93g~b528f4f773e8a566ea692506496c21f7

Analysts' recommendations: Outlook Therapeutics, Inc.

05-18	BTIG Downgrades Outlook Therapeutics to Neutral From Buy	MT
01-05	Chardan Adjusts Price Target on Outlook Therapeutics to $1 From $3, Maintains Neutral Rating	MT
29/09/25	Outlook Therapeutics Plans to Resubmit ONS-5010 Biologics License Application Before Year-End	MT
29/09/25	Outlook Therapeutics provides update on Type A Meeting with FDA	RE
29/08/25	Outlook Therapeutics Shares Fall After HC Wainwright Downgrade	MT
29/08/25	HC Wainwright Downgrades Outlook Therapeutics to Neutral From Buy, Adjusts Price Target to $1 From $3	MT
28/08/25	Guggenheim Downgrades Outlook Therapeutics to Neutral From Buy	MT
02/12/24	Chardan Downgrades Outlook Therapeutics to Neutral From Buy, Puts Price Target 'Under Review' After $53 Price Target	MT
27/03/24	BTIG Upgrades Outlook Therapeutics to Buy From Neutral, Price Target at $50	MT
15/02/24	Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target; Says Risk/Reward is Favorable for Lytenava BLA Resubmission	MT
15/02/24	Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target	MT
25/01/24	Guggenheim Upgrades Outlook Therapeutics to Buy From Neutral, Sets Price Target at $2	MT
25/01/24	Brookline Capital Upgrades Outlook Therapeutics to Buy From Hold, Price Target is $1.57	MT
27/12/23	Capital One Upgrades Outlook Therapeutics to Overweight From Equalweight With $5 Price Target	MT
31/08/23	Chardan Downgrades Outlook Therapeutics to Neutral From Buy	MT
31/08/23	HC Wainwright Downgrades Outlook Therapeutics to Neutral From Buy, Price Target is $1	MT
30/08/23	Brookline Capital Downgrades Outlook Therapeutics to Hold From Buy	MT
30/08/23	Cantor Fitzgerald Downgrades Outlook Therapeutics to Neutral From Overweight, Adjusts Price Target to $1 From $4.50	MT
30/08/23	BTIG Downgrades Outlook Therapeutics to Neutral From Buy	MT
13/07/23	Capital One Initiates Outlook Therapeutics With Overweight Rating, $5 Price Target	MT
03/04/23	Guggenheim Initiates Outlook Therapeutics at Buy With $5 Price Target	MT
06/02/23	Cantor Fitzgerald Initiates Outlook Therapeutics at Overweight With $4 Price Target	MT
06/01/23	HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating	MT
31/10/22	BTIG Starts Outlook Therapeutics at Buy With $7 Price Target	MT
13/09/22	Chardan Capital Starts Outlook Therapeutics at Buy With $10 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	OUTLOOK THERAPEUTICS, INC.					+610.04%
	LONZA GROUP AG					+17.6%
	REVOLUTION MEDICINES, INC.					+3.37%
	BEONE MEDICINES AG					+14.9%
	IQVIA HOLDINGS INC.					+10.38%
	CELLTRION, INC.					+36.76%
	MEDPACE HOLDINGS, INC.					-4.35%
	ASCENDIS PHARMA A/S					+20.5%
	EUROFINS SCIENTIFIC SE					+2.64%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-3.1%
	Average					+70.88%
	Weighted average by Cap.					+13.23%